Hematological Disorders

Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer in the field of medicine but also in the lives of the patients. Until the last approvals made by Novartis and Kite Pharma for B-NHLs, the field was conventionally treated with the combination known as R-CHOP (rituximab [Rituxan], cyclophosphamide [Cytoxan], doxorubicin [Adriamycin], vincristine [Oncovin], and prednisone). Sometimes an additional chemotherapy drug, etoposide (Vepesid, Toposar, Etopophos), is also added to the R-CHOP regimen, resulting in a drug combination c...